Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$87.25 USD

87.25
746,981

+2.40 (2.83%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $87.26 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BNTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 17,911 14,818 2,454 1,539 583
Receivables 2,527 7,529 14,649 190 14
Notes Receivable 0 0 0 0 0
Inventories 387 463 595 73 13
Other Current Assets 309 286 134 102 17
Total Current Assets 21,134 23,097 17,832 1,904 627
Net Property & Equipment 820 642 382 259 104
Investments & Advances 1,273 85 25 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 88 242 16 184 0
Intangibles 1,263 231 239 187 100
Deposits & Other Assets 90 7 1 1 0
Total Assets 24,900 24,527 18,729 2,649 893
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 383 215 189 117 23
Current Portion Long-Term Debt 30 38 154 10 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 569 628 1,856 0 0
Other Current Liabilities 1,259 2,228 1,920 565 130
Total Current Liabilities 2,241 3,109 4,119 692 155
Mortgages 0 0 0 0 0
Deferred Taxes/Income 43 7 79 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 207 186 203 264 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 497 95 257 125 186
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,988 3,396 4,658 1,082 341
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 269 262 291 281 260
Capital Surplus 1,331 1,926 1,981 1,262 293
Retained Earnings 21,390 19,842 11,692 0 0
Other Equity -1,066 -894 111 29 5
Treasury Stock 12 6 5 5 6
Total Shareholder's Equity 21,912 21,131 14,071 1,567 553
Total Liabilities & Shareholder's Equity 24,900 24,527 18,729 2,649 893
Total Common Equity 21,912 21,131 14,071 1,567 553
Shares Outstanding 237.70 242.60 242.50 226.20 226.20
Book Value Per Share 92.18 87.10 58.03 6.93 2.44

Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 18,626 17,009 17,911 17,141 16,964
Receivables 304 2,077 2,527 2,494 3,260
Notes Receivable 0 0 0 0 0
Inventories 366 375 387 452 489
Other Current Assets 391 379 309 319 238
Total Current Assets 19,687 19,840 21,134 20,407 20,951
Net Property & Equipment 935 871 820 793 754
Investments & Advances 1,493 1,723 1,273 1,407 1,499
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 110 99 88 227 261
Intangibles 1,330 1,292 1,263 1,122 547
Deposits & Other Assets 117 90 90 0 3
Total Assets 23,948 24,164 24,900 24,170 24,235
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 949 324 383 242 249
Current Portion Long-Term Debt 38 34 30 44 42
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 393 383 569 593 605
Other Current Liabilities 1,232 1,002 1,259 1,088 1,087
Total Current Liabilities 2,612 1,744 2,241 1,967 1,983
Mortgages 0 0 0 0 0
Deferred Taxes/Income 41 43 43 47 5
Convertible Debt 0 0 0 0 0
Long-Term Debt 236 223 207 176 182
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 520 497 357 358
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,409 2,485 2,988 2,547 2,529
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 268 270 269 271 271
Capital Surplus 1,327 22,449 1,331 1,337 1,553
Retained Earnings 20,074 0 21,390 21,012 20,875
Other Equity -1,118 -1,028 -1,066 -985 -984
Treasury Stock 12 12 12 12 10
Total Shareholder's Equity 20,539 21,679 21,912 21,623 21,706
Total Liabilities & Shareholder's Equity 23,948 24,164 24,900 24,170 24,235
Total Common Equity 20,539 21,679 21,912 21,623 21,706
Shares Outstanding 237.70 237.70 237.70 239.70 240.90
Book Value Per Share 86.41 91.21 92.18 90.21 90.10